ANKE BIO: The invested company PA3-17 injection has been approved to enter the critical Phase II clinical trial

ANKE BIO announced that recently, its affiliated companies, Boshengji Pharmaceutical Technology Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., received the Minutes of the communication meeting for Phase II of PA3-17 injection issued by the Drug Evaluation Center of the National Medical Products Administration, agreeing to the applicant's request to conduct a pivotal Phase II clinical trial for PA3-17 injection. PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7, independently developed by Boshengji Anke, which has received approval for new drug clinical trials for the treatment of adult relapsed and refractory CD7-positive hematologic and lymphatic malignancies